Scinai Immunotherapeutics is a biopharmaceutical company dedicated to the development of innovative biological products targeting inflammation and immunology (I&I) diseases, particularly autoimmune and infectious diseases. The company’s primary focus is on its proprietary nanosized antibodies, known as VHH-antibodies or NanoAbs, which are designed to address significant unmet medical needs in conditions such as psoriasis and asthma. Scinai collaborates with leading research institutions, including the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, to optimize the design and efficacy of these NanoAbs. Recent studies have demonstrated the potential of these antibodies in treating mild to moderate plaque psoriasis and in neutralizing various SARS-CoV-2 variants, showcasing their versatility and therapeutic promise.

In addition to its drug development efforts, Scinai operates a Contract Development and Manufacturing Organization (CDMO) that provides comprehensive services to pharmaceutical and biotech companies. This includes support throughout the drug development process, from initial development and manufacturing to clinical trial execution. Scinai's CDMO services emphasize cost-effectiveness, scalability, and adherence to stringent regulatory standards, with capabilities in process development, analytical methods, and cGMP manufacturing. The company’s state-of-the-art facilities in Israel are designed to meet both EMA and FDA GMP standards, ensuring high-quality production and compliance across all stages of drug development.

Israel

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products. Previously known as BiondVax Pharmaceuticals, the company has undergone significant changes, including a shift in focus and a rebranding to reflect a new strategic direction. Scinai Immunotherapeutics is also working on an innovative plaque psoriasis treatment that has shown encouraging preclinical results.

Scinai Immunotherapeutics

Company Details